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Superior mesenteric venous thrombosis (SMVT) is an uncommon but potentially life-
threatening disorder. We describe a cirrhotic patient with hepatocellular carcinoma who had
partial SMVT for at least 28 months. Our experience may help in the management of such
patients. The partial SMVT was not treated at the time of discovery because there was no
evidence of bowel infarction. Moreover, the patient had a tendency to bleed severely and
was in a poor condition. SMVT was followed using regular ultrasonography and the pattern
of SMVT did not change significantly during the follow-up period. A symptom that may
have been related to SMVT was abdominal colic pain after meals, which was sometimes
followed by diarrhea and/or nausea and vomiting. There was no evidence of bowel ischemia
or infarction during follow-up. Abdominal discomfort can be successfully treated using
anticholinergic drugs with or without analgesia.
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Superior mesenteric venous thrombosis (SMVT) is an
uncommon disorder [1–3], with no specific clinical
symptoms and signs. Early diagnosis is based on the
physician’s awareness of the disorder. SMVT is
clinically important because it has the potential to
cause life-threatening bowel ischemia [1–6]. SMVT
may be  id iopath ic ,  secondary  to  inher i ted
thrombophilic conditions, or acquired [2–6]. Liver
cirrhosis and hepatocellular carcinoma (HCC), which
are very common in Taiwan, are two acquired causes
of SMVT [2]. At autopsy [7] and peritoneoscopy [8–
10], macronodular cirrhosis coexists in 80–85% of
patients with HCC. SMVT in cirrhotic patients with
HCC may be caused by either portal hypertension or
malignant invasion. The methods used to treat benign
SMVT are quite different from those for malignant
SMVT. Moreover, patients with liver cirrhosis usually
demonstrate a tendency to bleed,  caused by
thrombocytopenia and coagulopathy. Therefore, it may
be very difficult to decide on how to manage SMVT in
cirrhotic patients with HCC. In this case report, we
describe a cirrhotic patient with HCC who had partial
SMVT for at least 28 months. Our experience may help
in the management of such patients.
CASE PRESENTATION
A 50-year-old man with a medical history of liver
cirrhosis and diabetes mellitus was admitted to our
© 2003 Elsevier. All rights reserved.
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institution because of gastrointestinal hemorrhage.
Blood pressure at admission was 126/72 mmHg and
pulse rate was 104. Laboratory tests revealed a
hemoglobin concentration of 7.5 g/dL, white blood
cell count of 2,400/mm3, platelet count of 33,000/mm3,
total bilirubin concentration of 6.5 mg/dL (direct
bilirubin, 5.2 mg/dL), albumin of 2.7 g/mL, aspartate
transaminase of 150 IU/L, alanine transaminase of 98
IU/L, prothrombin time of 16.5 seconds (control, 12
seconds), and serum alpha-fetoprotein concentration
of 387 ng/mL. Upper gastrointestinal endoscopy
showed rupture of the esophageal varices, which was
successfully treated using continuous vasopressin
therapy for 3 days in combination with two sessions of
endoscopic ligation of the varices. Abdominal
ultrasonography on the second day of hospitalization
showed evidence of liver cirrhosis with massive ascites
and a hepatic nodule measuring 3 cm at the right
posterior inferior segment of the liver. The portal
system was patent with no evidence of thrombosis.
Aspiration biopsy of the hepatic nodule was not
p e r f o r m e d  b e c a u s e  o f  a s c i t e s .  F o l l o w - u p
ultrasonography 2 months after the first examination
showed improvement in the ascites, slight enlargement
of the hepatic nodule, and partial SMVT near the
confluence with the splenic vein (Figure 1A). No
hepatofugal portal blood flow was detected using
color Doppler ultrasonography. Since the patient did
not show evidence of peritonitis, was in a poor
condition, and had a tendency towards severe bleeding,
the SMVT was not treated. He was well informed
about the possible symptoms of SMVT and was
instructed to take a small amount of food only in each
meal. Contrast-enhanced computerized tomography
(CT) also showed partial SMVT and excluded the
possibility of intestinal infarction (Figure 2). The
hepatic nodule was diagnosed as HCC based on
elevated serum alpha-fetoprotein and CT findings.
The patient underwent regular follow-up for HCC
and SMVT using ultrasonography at 3-month intervals.
The HCC was treated using transcatheter arterial
chemoembolization at five sessions over a period of 2
years. Prophylactic endoscopic ligation of the
esophageal varices was performed over four sessions
during follow-up. The ultrasonographic pattern of the
partial SMVT did not change significantly for at least
28 months (Figure 1B). During the follow-up period,
the patient frequently complained of colic pain around
the umbilical area after meals. This symptom was
Figure 1. (A) Color Doppler ultrasonography shows partial
thrombosis of the superior mesenteric vein. There is turbulent
blood flow around the thrombus. (B) B-mode real-time
ultrasonography performed 28 months after the color Doppler




sometimes followed by diarrhea and/or nausea and
vomiting. There was no evidence of bowel ischemia or
infarction during follow-up. Abdominal discomfort
was successfully treated with anticholinergic drugs,
with or without analgesia. The patient died 32 months
after the first admission to our institution due to
cellulitis of the legs caused by Vibrio vulnificus.
DISCUSSION
SMVT caused by inherited thrombophilic conditions
such as protein C and protein S deficiencies,
antithrombin III deficiency, dysfibrinogenemia, and
factor V Leiden deficiency is usually observed in young
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patients [2,6]. The patient in this case report was 50
years old and had no medical history of venous
thrombosis. Moreover, the pattern of SMVT did not
change significantly over time, indicating that it was
not caused by an inherited thrombophilic condition.
Focal or generalized abdominal inflammation,
abdominal surgery or trauma, portal hypertension,
invasion by malignant tumor, and oral contraceptive
use can cause acquired SMVT [2,3]. The SMVT in the
present case was not caused by tumor invasion as the
HCC nodule was far away from the SMVT. Moreover,
there was no hepatofugal portal blood flow and other
parts of the portal system were free of thrombosis. The
SMVT in our case was considered to be benign because
there was no significant change in its pattern during
long-term follow-up.
Endoscopic sclerotherapy with and without
continuous vasopressin therapy may also cause SMVT
[4]. Vasopressin therapy reduces portal blood flow via
reversible vasoconstriction of splanchnic arterial blood
vessels. This may cause stasis of portal blood flow in
patients with severe portal hypertension. The clot
induced by sclerotherapy may thus extend from the
varices to the portal system when vasopressin therapy
is used continuously for several days.  When
sclerotherapy is used without continuous vasopressin
therapy, SMVT may be caused by the injected
s c l e r o s a n t  a n d / o r  d i s t u r b a n c e  i n  p o r t a l
hemodynamics. In the present case, endoscopic ligation
therapy rather than sclerotherapy was used for
hemostasis. Although the patient also received
continuous vasopressin therapy for 3 days, there was
no evidence of thrombosis in other parts of the portal
system. Therefore, the SMVT in our case was not
caused by the extension of a clot from the varices to the
portal system. Endoscopic ligation therapy alone was
not considered to be a cause of SMVT because
prophylactic ligation therapy did not cause further
extension of the SMVT. The actual mechanism for
the development of SMVT in our case remains
unknown.
SMVT can be classified into acute and chronic
presentations. Patients with acute SMVT present with
symptoms of less than 4 weeks’ duration. Patients
presenting with symptoms of more than 4 weeks’
duration but without bowel infarction, or those with
SMVT diagnosed incidentally from clinically
insignificant findings on abdominal imaging, can be
classified as having chronic SMVT [2]. The patient in
our case had chronic SMVT.
The symptoms of SMVT are not specific. They
include abdominal pain, anorexia, diarrhea, nausea
and vomiting, gastrointestinal bleeding, and even
constipation [1–6]. The abdominal pain may vary from
a mild and tolerable discomfort to severe and
incapacitating distress. The most severe outcome of
SMVT is intestinal infarction. In the present case, the
symptom that may have been related to the thrombosis
was frequent colic pain around the umbilical area of
the abdomen after meals. Postprandial increase in
portal blood flow, which needs to pass through the
partially occluded superior mesenteric vein, may be
the cause of this abdominal discomfort. Instructing the
patient to eat only small meals may thus reduce the
severity of this discomfort. Anticholinergic drugs with
or without analgesia may be used in the management
of such patients.
Systemic anticoagulation, transcatheter clot lysis,
and surgical management are methods that can be
used to treat benign SMVT [1–3,5,6,11–14]. They are
usually applied immediately after the diagnosis is
made. Systemic anticoagulation is usually the first
choice for the treatment of benign SMVT because it is
not difficult to perform. Transcatheter clot lysis may
also be employed, but must be carried out by trained
professionals. These methods carry a high risk of
hemorrhage in patients with thrombocytopenia and/
or coagulopathy. Surgical intervention is mandatory
for cases with localized or diffuse peritonitis [2], but it
Figure 2. Contrast-enhanced computerized tomography shows
partial thrombosis of the superior mesenteric vein (arrow). There
is no evidence of edema of the bowel wall.
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carries a high operative risk. Regular follow-up may
be the treatment of choice for patients with benign
SMVT diagnosed incidentally from clinically
insignificant findings on abdominal imaging [3]. Local
irradiation therapy and/or systemic chemotherapy
may be considered in patients with malignant SMVT.
Irradiation therapy carries the risk of irradiation
enteritis. Systemic chemotherapy usually has severe
side effects, especially in bone marrow suppression.
In the present case, it was not possible to determine
whether the SMVT was benign or malignant at the
time of discovery because it was impossible to obtain
specimens for pathologic examination. Moreover, the
patient had a tendency towards severe bleeding and
did not show evidence of peritonitis. Therefore, he
received conservative treatment with regular follow-
up using ultrasonography rather than aggressive
treatment.
CONCLUSION
The present case shows that partial SMVT in a cirrhotic
patient with HCC may remain in a static condition for
a long period. In clinical practice, it is impossible to
predict at the time of discovery whether the partial
SMVT will progress to complete occlusion. It may also
be very difficult to determine the nature of SMVT in a
cirrhotic patient with HCC at the time of discovery.
R e g u l a r  f o l l o w - u p  o f  p a r t i a l  S M V T  u s i n g
ultrasonography may be one choice for patients with
a tendency towards severe bleeding. Aggressive
management of partial SMVT should be started in
p a t i e n t s  d e m o n s t r a t i n g  p r o g r e s s i o n  o f  t h e
thrombosis.
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